Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
|Articles|June 9, 2014
Supplements and Featured Publications
- Improving Clinical and Managed Care Outcomes in Rheumatoid Arthritis: New Guidelines, Therapies, and
- Volume 20
- Issue 7 Suppl
Post Test: Improving Clinical and Managed Care Outcomes in Rheumatoid Arthritis: New Guidelines, Therapies, and Challenges
Advertisement
Pharmacy Credit
Instructions for Receiving Continuing Pharmacy Education (CPE) Credit: Testing and Grading Information
This activity is free online at www.ajmc.com/ce and at www.PharmacyTimes.org, where you will be directed to the online pre-test and posttest, activity evaluation, and request for credit. Instant online grading along with a downloadable statement of credit are also available.
Testing and Grading Directions
- Each participant evaluating the activity and achieving a passing grade of 70% or higher on the online posttest will be eligible to receive a CPE statement of credit.
- Participants receiving a failing grade on the exam will be notified and permitted to take 1 reexamination at no cost.
- To receive credit, go to www.ajmc.com/ce or www.pharmacytimes.org, locate this activity in the CE course list, click on the online pre- and posttest link, and complete the online activity evaluation form to receive your statement of credit.
Release Date: May 21, 2014
Expiration Date: May 21, 2016
Articles in this issue
over 12 years ago
Managed Care Implications in Managing Rheumatoid ArthritisAdvertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
5